NewLimit’s $435 M raise sparks hope, but also caution for real‑world use
Posted by dominic539 in Longevity & Anti-Aging - 1 points, 0 comments.
I just read the Stat News piece about NewLimit pulling in $435 million to start its first human trial on a liver‑focused rejuvenation therapy. The company says the drug will target senescent cells and improve metabolic health, which sounds like the kind of downstream benefit many of us hope for from NAD+ boosters or rapamycin.
For me the headline is exciting, but I remain skeptical until we see actual safety data. Most of the hype around senolytics comes from animal models, and human trials often reveal unexpected side effects. As a pharmacist I worry about off‑target effects, especially in people with pre‑existing liver issues. Also, the article glosses over the fact that even if the trial succeeds, the therapy will likely be expensive and not widely accessible for ordinary biohackers.
Do you think the influx of VC money into anti‑aging biotech will speed up credible clinical evidence, or will it just create more hype and pricey “longevity drugs” that never reach the average person?
Community discussion - research and educational context only. Not medical advice.